Eutropoflavin

Chemical compound
  • None
Identifiers
  • 2-[4-(dimethylamino)phenyl]-7,8-dihydroxy-4H-chromen-4-one
CAS Number
  • 1205548-04-4
PubChem CID
  • 44610701
ChemSpider
  • 26630138
UNII
  • B2M862MR4W
ChEMBL
  • ChEMBL1800922
CompTox Dashboard (EPA)
  • DTXSID901045822 Edit this at Wikidata
Chemical and physical dataFormulaC17H15NO4Molar mass297.310 g·mol−13D model (JSmol)
  • Interactive image
  • CN(C)c1ccc(cc1)c2cc(=O)c3ccc(c(c3o2)O)O
InChI
  • InChI=InChI=1S/C17H15NO4/c1-18(2)11-5-3-10(4-6-11)15-9-14(20)12-7-8-13(19)16(21)17(12)22-15/h3-9,19,21H,1-2H3
  • Key:YPAYCZOHGRSGJS-UHFFFAOYSA-N

Eutropoflavin (4'-Dimethylamino-7,8-dihydroxyflavone) is a synthetic flavone and selective small-molecule agonist of TrkB, the main receptor of brain-derived neurotrophic factor (BDNF), which was derived from structural modification of tropoflavin (7,8-DHF).[1][2][3][4] Relative to tropoflavin, eutropoflavin possesses higher agonistic activity at TrkB, is significantly more potent than tropoflavin both in vitro and in vivo, and has a longer duration of action (peaking at 4 hours and "partially decaying" at 8~16 hours in rodents).[1][3] The compound has been found to produce neuroprotective and neurogenic effects in the brain and spinal cord as well as antidepressant-like effects in animals.[1][3][4][5]

See also

References

  1. ^ a b c Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, et al. (December 2010). "A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect". Journal of Medicinal Chemistry. 53 (23): 8274–86. doi:10.1021/jm101206p. PMC 3150605. PMID 21073191.
  2. ^ Liu X, Chan CB, Qi Q, Xiao G, Luo HR, He X, Ye K (October 2012). "Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression". Journal of Medicinal Chemistry. 55 (19): 8524–37. doi:10.1021/jm301099x. PMC 3491656. PMID 22984948.
  3. ^ a b c Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Translational Neurodegeneration. 5 (1): 2. doi:10.1186/s40035-015-0048-7. PMC 4702337. PMID 26740873.
  4. ^ a b Zeng Y, Wang X, Wang Q, Liu S, Hu X, McClintock SM (November 2013). "Small molecules activating TrkB receptor for treating a variety of CNS disorders". CNS & Neurological Disorders Drug Targets. 12 (7): 1066–77. doi:10.2174/18715273113129990089. PMID 23844685.
  5. ^ Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, et al. (June 2013). "Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease". Human Molecular Genetics. 22 (12): 2462–70. doi:10.1093/hmg/ddt098. PMC 3658168. PMID 23446639.
  • v
  • t
  • e
Flavones and their conjugates
Aglycones
Monohydroxyflavone
Dihydroxyflavones
Trihydroxyflavones
Tetrahydroxyflavones
Pentahydroxyflavones
O-methylated flavones
Glycosides
of apigenin
of baicalein
of hypolaetin
  • Hypolaetin 8-glucoside
  • Hypolaetin 8-glucuronide
of luteolin
Acetylated
  • Artocarpetin A
  • Artoindonesianin P
  • Sulfated glycosidesPolymersDrugs
    • v
    • t
    • e
    Angiopoietin
    • Kinase inhibitors: Altiratinib
    • CE-245677
    • Rebastinib
    CNTF
    EGF (ErbB)
    EGF
    (ErbB1/HER1)
    ErbB2/HER2
    • Agonists: Unknown/none
    ErbB3/HER3
    ErbB4/HER4
    FGF
    FGFR1
    FGFR2
    • Antibodies: Aprutumab
    • Aprutumab ixadotin
    FGFR3
    FGFR4
    Unsorted
    HGF (c-Met)
    IGF
    IGF-1
    • Kinase inhibitors: BMS-754807
    • Linsitinib
    • NVP-ADW742
    • NVP-AEW541
    • OSl-906
    IGF-2
    • Antibodies: Dusigitumab
    • Xentuzumab (against IGF-1 and IGF-2)
    Others
    • Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
    • Trofinetide
    LNGF (p75NTR)
    • Aptamers: Against NGF: RBM-004
    • Decoy receptors: LEVI-04 (p75NTR-Fc)
    PDGF
    RET (GFL)
    GFRα1
    GFRα2
    GFRα3
    GFRα4
    Unsorted
    • Kinase inhibitors: Agerafenib
    SCF (c-Kit)
    TGFβ
    • See here instead.
    Trk
    TrkA
    • Negative allosteric modulators: VM-902A
    • Aptamers: Against NGF: RBM-004
    • Decoy receptors: ReN-1820 (TrkAd5)
    TrkB
    TrkC
    VEGF
    Others
    Stub icon

    This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

    • v
    • t
    • e